ArticleFrontiers in bioengineering and biotechnology2026
Pullulan-dextran composite beads as bone fillers: from material design and industrial production to clinical application in oral surgery.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing biomaterials from natural polysaccharides for medical applications presents significant challenges in terms of biocompatibility, scalability, and regulatory compliance. We report here the full development and preclinical validation of 250-300 µm pullulan-dextran-hydroxyapatite microbeads for bone regeneration, intended for use in sinus lift procedures. This class III medical device was fabricated using two pharmaceutical-grade, biodegradable, and biocompatible polysaccharides (pullulan and dextran) that were crosslinked without the use of organic solvents and embedded with hydroxyapatite microparticles. Industrial-scale production of 59 batches achieved batch-to-batch reproducibility, comprehensive physicochemical characterizations, stability, sterilization, and packaging in syringes under Good Manufacturing Practices (GMP). Preclinical validation included
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.